Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
WELIREG (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
WELIREG
Date registered
Evaluation commenced
Decision date
Approval time
220 (255 working days)
Active ingredients
belzutifan
Registration type
EOI
Indication
WELIREG (belzutifan) is now also indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed cell death 1/ligand 1 (PD-1/L1) and a vascular endothelial growth factor (VEGF)-targeted therapy.